Institut Curie Names Intel Lead Partner to Implement High-Performance Computing & Artificial Intelligence in Accelerating Gen...
May 23 2018 - 9:00AM
Business Wire
Institut Curie and Intel initiate a pioneering collaboration to
develop, use and implement innovative bioinformatics tools,
pipelines and techniques to improve the use of molecular profiling
across both research and clinical oncology settings.
Precision medicine for cancer requires the delivery of
individually adapted medical care based on the genetic
characteristics of each patient. The last decade witnessed the
development of high-throughput technologies such as next-generation
sequencing, which paved their way in the field of oncology. While
the cost of these technologies decreases, we are facing an
exponential increase in the amount of data produced. In order to
open access to precision medicine-based therapies to more patients,
healthcare providers have to rationalize both their data production
and utilization. This requires the implementation of cutting-edge
technologies: high-performance computing and artificial
intelligence (AI).
Before making a therapeutic decision based on the genome
interpretation of a cancer, the physician can be presented with an
overwhelming number of gene variants. In order to identify key
actionable variants that can be targeted by treatments, the
physician needs tools to sift through this large volume of
variants. While the use of AI in genome interpretation is still
nascent, it is growing rapidly, acting as a filter to dramatically
reduce the number of variants and providing invaluable help to
physicians. The mastering of high-performance computing methods on
modern hardware infrastructures is becoming a key factor in the
cancer genome interpretation process while being efficient,
cost-effective and adjustable over time.
The pioneer collaboration initiated between the Curie Institute
Bioinformatics platform and Intel aims at answering those
challenges by defining a leading model in France and Europe. This
collaboration will grant Institut Curie access to Intel experts for
defining high-performance computing and artificial intelligence
infrastructure and ensuring its optimization in order to implement
the Intel Genomics ecosystem partner solutions and best practices,
for example the Broad Institute for Cancer Genomics pipeline
optimization. Also anticipated is the development of additional
tailored tools needed to integrate and analyze heterogeneous
biomedical data. The collaboration will implement Intel® Select
Solutions for Genomics Analytics based on Intel® Xeon® Scalable
processors and Intel® Omni-Path Architecture.
“Artificial intelligence holds great promise for medical
progress including genomics,” said Brian Krzanich, Intel CEO. “The
Intel-Institut Curie collaboration is one more example of Intel’s
commitment to the development of bold artificial intelligence
research for the good of humanity.”
“Collaborating with Intel, Institut Curie will develop, use and
implement Innovative Bioinformatics technologies to improve time to
diagnosis, diagnostic accuracy, targeted treatment recommendations,
and provide a better understanding of application needs to develop
features that are needed for the healthcare sector,” said Emmanuel
Barillot, head of the Institut Curie Bioinformatics platform and
director of the Bioinformatics, Biostatistics, Epidemiology and
Computational Systems Research Unit (U900, Institut Curie /INSERM/
Mines Paris Tech).
Amaury Martin, lead of Institut Curie Technology Transfer and
Industrial Partnerships Office and director of the Institut Carnot
Curie Cancer said, “This agreement with Intel, the world leader in
the sector, marks a major step in the collaboration between
Institut Curie and companies. It is a mark of recognition for the
Institut Curie in the field of genetics, bioinformatics and
precision medicine, and its unique model ranging from basic
research to care. This agreement is undeniably an additional asset
for the success of the Paris region platform SeqOIA co-founded
between the APHP, Gustave-Roussy and Institut Curie within the
framework of the France Medicine Genomic 2025 Plan.”
About Intel
Intel (NASDAQ: INTC) is a world leader in computing innovation.
The company designs and builds the essential technologies that
serve as the foundation for the world’s computing devices.
Additional information about Intel is available at
newsroom.intel.com and blogs.intel.com.
About Institut Curie
Institut Curie, a leading player in the fight against cancer,
combines a leading French research center in oncology and a
state-of-the-art hospital group that treat all types of cancer,
including the rarest. Founded in 1909 by Marie Curie, the Institut
Curie brings together more than 3,300 researchers, physicians and
healthcare professionals around its three missions: care, research
and teaching. As a private foundation recognized for public
utility, Institut Curie is authorized to receive donations and
bequests and can, thanks to the support of its donors, accelerate
discoveries and thus improve the treatment and the quality of life
of the patients.
For more information: www.curie.fr.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180523005492/en/
Institut CurieHélène Bléher, + 33 (0)1 41 34 18
65hbleher@hopscotch.frorIntelMikael Moreau, +33 (0) 1 58 87 72
29mikael.moreau@intel.com
Intel (NASDAQ:INTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intel (NASDAQ:INTC)
Historical Stock Chart
From Sep 2023 to Sep 2024